New formulation of non-Hodgkin Lymphoma drug approved
European regulators have approved a subcutaneous form of MabThera for non-Hodgkin Lymphoma. This reduces patient treatment time from 2.5 hours to 5 minutes.
Up to now, the approved way of administering the drug was intravenous.
The green light for Roche's new MabThera formulation follows on from the European approval for a subcutaneous form of the breast cancer drug Herceptin last September.
Last November, U.S. health regulators approved its drug Gazyva as a treatment for chronic lymphocytic leukemia (CLL). Roche is also testing the drug in patients with non-Hodgkin's Lymphoma.
The drugmaker has also won approval for two new breast cancer drugs, Perjeta and Kadcyla.
Source: Reuters: http://www.reuters.com/article/2014/03/28/roche-mabthera-subcut-idINL5N0MP0XE20140328